

Special Issue

Lung Cancer & COVID 19: Lessons, Experiences, Strategies

Message from the Guest Editors

Cancer patients are highly vulnerable to SARS-CoV-2 infections due to several causes, including their immunocompromised state due to antineoplastic therapies, use of steroids, comorbidities and frequently advanced age, and frequent hospital visits. The clinical pictures of the infection can vary from mild flu-like conditions to severe pneumonia, which can evolve to acute respiratory alveolar damage (ARDS) and multiorgan failure. Moreover, the cytokine storm is implicated in the generation of aberrant immunological responses against the virus, which ultimately produce lung parenchymal acute and severe damage responsible for evolution to chronic fibrosis and, in worse cases, patient death. The goal of the present issue is to summarize, according to a multidisciplinary perspective, the lessons and experiences derived from the pandemic waves and to design strategies for future co-existence with SARS-CoV-2 to ensure safer and better outcomes for cancer patients.

Guest Editors

Dr. Giulia M. Stella

Dr. Torsten Gerriet Blum

Prof. Dr. Andrea Bianco

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/108903

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)